Professor Naomi Allen
- Accurately estimating the burden of disease using electronic health records
- An analysis of the measurement and mechanisms of health inequalities
- Automated risk factor discovery for large-scale biobank data
- Hormones, growth factors and health outcomes in middle and old age: a PheWAS approach in UK Biobank
- How does obesity cause cancer? Investigating potential mechanisms by metabolomics
BSc, MSc, DPhil
Professor in Epidemiology
- Clinical Trial Service Unit
Naomi Allen is a Professor in Epidemiology, based in the Clinical Trial Service Unit and Epidemiological Studies Unit. She joined UK Biobank as Senior Epidemiologist in 2011, and became Chief Scientist in 2019, where she is responsible for following-up participants both through linkage with routine health-related datasets, and through web-based questionnaires. She is also involved in developing the scientific strategy for future enhancements for the study. Her research interest is largely in the role of diet, obesity and circulating biomarkers in cancer development. She is co-Principal Investigator of the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group, which aims to conduct individual pooled analyses of the relationship between circulating biomarkers and prostate cancer risk from cohort studies from around the world.
Physical activity in relation to circulating hormone concentrations in 117,100 men in UK Biobank.
Watts EL. et al, (2021), Cancer Causes Control, 32, 1197 - 1212
Human cytomegalovirus and risk of incident cardiovascular disease in UK Biobank
Hamilton E. et al, (2021), The Journal of Infectious Diseases
United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8.
Caleyachetty R. et al, (2021), J Am Coll Cardiol, 78, 56 - 65
Prospective analysis of circulating metabolites and endometrial cancer risk.
Dossus L. et al, (2021), Gynecol Oncol
Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank.
Watts EL. et al, (2021), Int J Cancer, 148, 2274 - 2288